5-(6-(dimethylamino)pyridin-3-yl)-4-methoxy-N-(2-adamantanyl)pyrimidin-2-amine | 1229184-97-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-(6-(dimethylamino)pyridin-3-yl)-4-methoxy-N-(2-adamantanyl)pyrimidin-2-amine
• 英文别名: N-(2-adamantyl)-5-[6-(dimethylamino)pyridin-3-yl]-4-methoxypyrimidin-2-amine
• CAS: 1229184-97-7
• 化学式: C₂₂H₂₉N₅O
• 分子量: 379.505
• InChiKey: CWCXKSKASRUJPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  63.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Pyrimidine Compounds and Methods of Making and Using Same
  申请人：Chiang Phoebe

  公开号：US20110281873A1

  公开（公告）日：2011-11-17

  Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.

  本文披露了嘧啶基化合物，被认为是囊性纤维化跨膜调节器（CFTR）的调节剂，并提供了制备和使用它们的方法。还提供了药物组合物和治疗与囊性纤维化跨膜调节器相关的疾病的方法，例如气道炎症，囊性纤维化等。
• US8513242B2
  申请人：——

  公开号：US8513242B2

  公开（公告）日：2013-08-20
• [EN] PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS DE PYRIMIDINE ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：CYSTIC FIBROSIS FOUNDATION THE

  公开号：WO2010068863A2

  公开（公告）日：2010-06-17

  Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.
• [EN] ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS<br/>[FR] COMPOSÉS ARYLPYRIMIDINES ET THÉRAPIE DE COMBINAISON COMPRENANT CEUX-CI POUR TRAITER UNE MUCOVISCIDOSE ET DES TROUBLES APPARENTÉS
  申请人：CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC

  公开号：WO2011008931A2

  公开（公告）日：2011-01-20

  Provided herein are pharmaceutical compositions comprising an arylpyrimidine compound that modulates the activity of cystic fibrosis transmembrane regulator (CFTR) protein and a second compound that modulates the activity of a CFTR protein. Also provided are methods of treating a disorder associated with CFTR protein function by administering an arylpyrimidine compound that modulates the activity of a CFTR protein and a second compound that modulates the activity of a CFTR protein. The combination therapy can be used to treat, for example, airway inflammation and cystic fibrosis.